Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment.
Clin Chest Med
69 - 83.
Idiopathic pulmonary fibrosis (IPF) is a progressive disease of unknown cause that conveys a dismal prognosis. In the United States there are currently no licensed therapies for treatment of IPF. The development of effective IPF clinical trials networks across the United States and Europe, however, has led to key developments in the treatment of IPF. Advances in understanding of the pathogenetic processes involved in the development of pulmonary fibrosis have led to novel therapeutic targets. These developments offer hope that there may, in the near future, be therapeutic options available for treatment of this devastating disease.
|Title:||Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment.|
|Keywords:||Acute Disease, Clinical Trials as Topic, Connective Tissue Growth Factor, Cytokines, Eicosanoids, Humans, Idiopathic Pulmonary Fibrosis, Interleukin-13, NADPH Oxidase, Oxidative Stress, Protein Kinases, Signal Transduction, Th2 Cells, Transforming Growth Factor beta, Treatment Failure|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of)|
Archive Staff Only